drugset / Trial / NCT06099184

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

NCT06099184

Phase 2 Completed 27 enrolled EyePoint Pharmaceuticals, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept

Timeline

Start
2024-01-15
Primary completion
2024-10-24
Completion
2024-10-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic 2 mg Intravitreal
Subject CM082 Unknown 1343 ug Intravitreal
Subject CM082 Unknown 2686 ug Intravitreal